Back to News
Market Impact: 0.2
Lucid Capital Markets Initiates Coverage of Faeth Therapeutics with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Lucid Capital Markets initiated coverage of Faeth Therapeutics (NASDAQCM:FTH) with a Buy rating on September 14, 2026. FTH closed at $39.02 on the rating date, following a prior close of $37, signaling a modestly positive analyst catalyst for the biotech stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
FTH0.55
More News
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Tech gets crushed, defensive stocks shine. How we're making sense of it all
- Anthropic's IPO push includes a big bet on life sciences
- Investing.com’s stocks of the week
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Google lost nearly half a trillion this week. Here's how Mike Khouw is trading it